Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC in Diabetic Kidney Disease
NCT06654921Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Jan 2025
- Primary completion
- Dec 2025
01
Overview
Randomised, double-blind trial (2 arms), sponsored by Capital Medical University. Primary endpoint: Tolerability of RIC at 6 months. Planned start Jan 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06654921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654921.